Literature DB >> 28201767

Marginal structural models in clinical research: when and how to use them?

Tyler Williamson1,2, Pietro Ravani1,3.   

Abstract

Marginal structural models are a multi-step estimation procedure designed to control for the effect of confounding variables that change over time, and are affected by previous treatment. When a time-varying confounder is affected by prior treatment standard methods for confounding control are inappropriate, because over time the covariate plays both the role of confounder and mediator of the effect of treatment on outcome. Marginal structural models first calculate a weight to assign to each observation. These weights reflect the extent to which observations with certain characteristics (covariate values) are under-represented or over-represented in the sample with the respect to a target population in which these characteristics are balanced across treatment groups. Then, marginal structural models estimate the outcome of interest taking into account these weights. Marginal structural models are a powerful method for confounding control in longitudinal study designs that collect time-varying information on exposure, outcome and other covariates.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  bias; confounding; inverse probability of treatment weight; longitudinal study design; marginal methods

Mesh:

Substances:

Year:  2017        PMID: 28201767     DOI: 10.1093/ndt/gfw341

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  20 in total

1.  Health Economics and Outcomes Research of Wound Care: Overview of Methodology.

Authors:  Adrienne M Gilligan
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-11-12       Impact factor: 4.730

2.  Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies.

Authors:  Kathryn Richardson; George M Savva; Penelope J Boyd; Clare Aldus; Ian Maidment; Eduwin Pakpahan; Yoon K Loke; Antony Arthur; Nicholas Steel; Clive Ballard; Robert Howard; Chris Fox
Journal:  Health Technol Assess       Date:  2021-01       Impact factor: 4.014

3.  Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.

Authors:  Scott Sibbel; Katherine McKeon; Jiacong Luo; Karl Wendt; Adam G Walker; Tara Kelley; Rachael Lazar; Meredith L Zywno; Jeffrey J Connaire; Francesca Tentori; Amy Young; Steven M Brunelli
Journal:  J Am Soc Nephrol       Date:  2021-11-17       Impact factor: 10.121

4.  Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study.

Authors:  Mikkel Højlund; Kjeld Andersen; Martin T Ernst; Christoph U Correll; Jesper Hallas
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

5.  Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism.

Authors:  Melissa Soohoo; Yoshitsugu Obi; Matthew B Rivara; Scott V Adams; Wei Ling Lau; Connie M Rhee; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Onyebuchi A Arah; Rajnish Mehrotra; Elani Streja
Journal:  Am J Nephrol       Date:  2022-02-28       Impact factor: 4.605

6.  Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Authors:  Rupal Mehta; Xuan Cai; Jungwha Lee; Dawei Xie; Xue Wang; Julia Scialla; Amanda H Anderson; Jon Taliercio; Mirela Dobre; Jing Chen; Michael Fischer; Mary Leonard; James Lash; Chi-Yuan Hsu; Ian H de Boer; Harold I Feldman; Myles Wolf; Tamara Isakova
Journal:  Am J Kidney Dis       Date:  2019-12-19       Impact factor: 8.860

7.  Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.

Authors:  Edouard L Fu; Marie Evans; Catherine M Clase; Laurie A Tomlinson; Merel van Diepen; Friedo W Dekker; Juan J Carrero
Journal:  J Am Soc Nephrol       Date:  2020-12-28       Impact factor: 10.121

8.  Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis.

Authors:  Shunsuke Mori; Yukitomo Urata; Tamami Yoshitama; Yukitaka Ueki
Journal:  RMD Open       Date:  2021-05

9.  Uncontrolled Pain and Risk for Depression and Behavioral Symptoms in Residents With Dementia.

Authors:  Yu-Jung Jenny Wei; Cheng Chen; Roger B Fillingim; Steven T DeKosky; Siegfried Schmidt; Marco Pahor; Laurence Solberg; Almut G Winterstein
Journal:  J Am Med Dir Assoc       Date:  2021-06-03       Impact factor: 7.802

10.  Long-term weight changes and risk of rheumatoid arthritis among women in a prospective cohort: a marginal structural model approach.

Authors:  Nathalie E Marchand; Jeffrey A Sparks; Susan Malspeis; Kazuki Yoshida; Lauren Prisco; Xuehong Zhang; Karen Costenbader; Frank Hu; Elizabeth W Karlson; Bing Lu
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.